Koneksa Health Announces Senior Leadership Appointments
Vik Shah Named COO; Elena Izmailova, Ph.D. Named Chief Scientific Officer; Gol Ophir Named Head of Business Development
NEW YORK, Dec. 6, 2018 /PRNewswire/ -- Koneksa Health, a private company that enables the biopharmaceutical industry to develop new medicines with fewer patients, announced today that three industry leaders have been appointed to senior roles with the company. Vik Shah will serve as Chief Operating Officer; Elena Izmailova, Ph.D., joins as the company's Chief Scientific Officer; and Gol Ophir is named Head of Business Development.
Vik joins Koneksa with a deep background in healthcare information technology, having spent a decade with Medidata, eventually as SVP of Applications and Platforms. More recently, Vik served as COO at two early-stage technology companies. At Koneksa, Vik's role will be responsible to scale all facets of the business, driving operational and financial excellence, as well as developing meaningful and mutually productive partnerships.
Elena was most recently Senior Director, Novel Data Streams and Devices, at Takeda, where she established the strategy and road map for digital device implementation and data collection in clinical trials. Previously as a leader in the global translational medicine group, she established the company's biomarker assay development network to ensure seamless transitions from discovery to development. Her experience in biomarker development and validation extends over fifteen years, since joining Millennium Pharmaceuticals (later acquired by Takeda) from the Children's Hospital/HMS and Whitehead Institute/MIT in 2003.
Gol brings experience building technology business development capabilities in the financial sector and the pharmaceutical industry. He has deep experience developing new businesses and offerings across a range of industries. At Morgan Stanley, Gol created the first technology business development function at a major Wall Street firm. He also has extensive experience as an operating executive both for Morgan Stanley and Bridgewater Associates, which has been instrumental as he develops new technology-enabled businesses and partnerships. More recently, Gol was EVP and Chief Risk Officer for Business Services at Citizens Bank.
"I'm proud to welcome these three executives, whose diverse backgrounds and depth of expertise will help propel Koneksa as we move into our next chapter of growth," said Koneksa CEO Chris Benko. "Vik, Elena and Gol each have a unique experiences that complement our team and will prepare us for the future. Vik's track record helping companies to scale successfully, Elena's perspective as a translational researcher and industry leader in the emerging field of digital biomarkers, and Gol's expertise in business development in highly regulated, data-intensive industries - are all powerful additions to our management team. We're delighted to have them join us and know their leadership will be instrumental as Koneksa takes on new and greater challenges."
About Koneksa Health
Koneksa Health is a private company that enables the biopharmaceutical industry to develop new medicines with fewer patients. By unlocking the potential of real-world data from remote, wearable, and other digital technologies, Koneksa speeds up the time required to understand how a drug is working and helps to develop real-world evidence for how medicines can impact the daily lives of patients.
For more information, please visit http://koneksahealth.com/ExecAnnounceDec
Koneksa Media Contact: Trevor Bratton, email@example.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/koneksa-health-announces-senior-leadership-appointments-300760967.html
SOURCE Koneksa Health